Despite consistent recommendations and growing clinical evidence, uptake of SGLT2i and GLP1 RA therapies in people with type 2 diabetes and cardiorenal comorbidities has been slow. There is also relatively little research on ethnic differences in those starting second-line therapy. This is an omission, as ethnic minority groups have higher rates of morbidity and mortality associated with type 2 diabetes.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- From symptom to diagnosis
Oncology – Prostate carcinoma
- Stress-hyperglycemia quotient and machine learning
Prediction of mortality after heart surgery
- Supply models in Switzerland
Health 2040 research project
- Pathogenesis, diagnostics and therapeutic interventions
Sarcopenia in Parkinson’s disease
- Casuistry
63-year-old with tracheobronchopathia osteoplastica
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline
Management of acute coronary syndrome
- Pustular psoriasis
What is known about inflammatory mechanisms in PPP and GPP?
- Diabetes-related cardiovascular diseases